Print
Email
Print Edition StoriesWednesday, October 28, 2009
Interlace device lands FDA clearance
By Mass High Tech staff
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Interlace Medical Inc. reports it has received clearance from the U.S. Food and Drug Administration for a process for a gynecological treatment.
Framingham-based Interlace received 510K clearance from the FDA to market its MyoSure Hysteroscopic Tissue Removal System for the removal of submucosal fibroids and polyps. The MyoSure system is intended to allow physicians to quickly remove fibroids in one step, avoiding risks associated with energy-based devices. The treatment is also intended to provide women with an incision-free treatment alternative that preserves uterine form and function, the company said.
Interlace raised $20.5 million in its Series C funding round in June from investment leaders Baird Venture Partners and HLM Venture Partners, as well as Hambrecht & Quist Capital Management LLC and Aperture Venture Partners and returning backers New Leaf Venture Partners and Spray Venture Partners. The funding was expected to apply to the commercialization of the MyoSure device.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
